コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 lobulin G and lambda light chain detected on immunofixation.
2 ells in addition to negative serum and urine immunofixation.
3 discrete or localized band were subjected to immunofixation.
4 0 years and subjected to electrophoresis and immunofixation.
5 ht to have a localized band was subjected to immunofixation.
6 whom myeloma protein was detectable only by immunofixation.
7 -h urine total protein, electrophoresis, and immunofixation.
8 as confirmed to be immunoglobulin Mlambda at immunofixation.
9 n levels; serum protein electrophoresis with immunofixation; 24-hour urine protein electrophoresis; a
10 ic plasma cell levels is more sensitive than immunofixation and can identify which patients may benef
11 Pre-beta-1 HDL levels were quantified by immunofixation and nondenaturing 2-dimensional gel elect
13 interference of therapeutic antibodies with immunofixation and serum protein electrophoresis assays
14 for monoclonal (M)-proteins (electrophoresis/immunofixation) and kappa-lambda free light chains (FLCs
15 ete responses (CRs), four near CRs (positive immunofixation), and 12 partial responses; six patients
16 Serum and urine protein electrophoresis and immunofixation, as well as analyses of serum free light
17 These additional protein bands, detected by immunofixation electrophoresis (IFE), could be due to al
18 in (M-protein)-negative status on both serum immunofixation electrophoresis (sIFE) and urine (uIFE) i
21 as a 25-fold improvement in sensitivity over immunofixation electrophoresis and can potentially provi
22 Antibody clonality was assessed by means of immunofixation electrophoresis and mass spectrometry.
23 d monoclonal gammopathies below the clinical immunofixation electrophoresis detection level (<0.2 g/L
24 tion electrophoresis (sIFE) and urine (uIFE) immunofixation electrophoresis for classification of com
25 7%); by serum protein electrophoresis and/or immunofixation electrophoresis in 21 patients (77.8%), a
26 r plasma cell dyscrasias were evaluated with immunofixation electrophoresis of serum and urine specim
27 made using serum free light chain assay and immunofixation electrophoresis to exclude light chain am
28 samples with sufficient serum remaining, and immunofixation electrophoresis was done for all samples
30 ), positive urine protein electrophoresis or immunofixation electrophoresis, serum creatinine, C3 lev
37 surement, serum protein electrophoresis with immunofixation, fasting glucose measurement, and glucose
39 MGUS was detected in 55 (6%) relatives, and immunofixation identified 28 additional relatives for an
40 with multiple myeloma who achieved negative immunofixation in the serum and urine after therapy and
41 001, respectively) and in patients achieving immunofixation-negative complete response (CR; PFS, P =
42 ma cells were detectable in 27% (9 of 33) of immunofixation-negative complete-remission patients.
43 atients had a significantly shorter PFS than immunofixation-negative patients with no detectable neop
45 atients (68%), including two CRs (6%), three immunofixation-positive CRs (9%), 11 PRs (32%), and seve
46 ionuclide bone scintigraphy, serum and urine immunofixation, sFLC assay, eGFR measurement and echocar
47 the serum-free light chain ratio to negative immunofixation studies did not negate the need for BM st
48 etter correlation with serum cryoprecipitate immunofixation than conventional immunofluorescence with
49 ce of a serum or urine monoclonal protein on immunofixation together with a sFLC ratio falling within
50 ormal FLC ratio and negative serum and urine immunofixation), very good partial response (difference